Clinical Study

A Phase 3 Prospective, Randomized, Double-Blind, Multicenter, Study Of The Efficacy And Safety Of Lanreotide Autogel/ Depot 120Mg Plus Bsc Vs Placebo

Posted Date: May 15, 2019

  • Investigator: John Morris
  • Type of Study: Drug

The purpose of this research study is to evaluate effectiveness and safety of lanreotide for treating neuroendocrine tumors (NET) of the Lungs. In this study, lanreotide will be compared with placebo treatment (i.e. dummy treatment that looks like the real treatment but contains no active ingredient

Criteria:

To Be Eligible To Participate In This Study, Patients Must Have Neuroendocrine Tumor Of The Lungs.

Keywords:

A-Us-52030-328, Cancer, Lung, Lung Cancer, Phase I

For More Information:

Uc Cancer Center
(513) 584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.